Study Results, Updated Organization Structures, Appointments, and Technical Updates - Analyst Notes on Johnson & Johnson, Pfizer, Teva, Express Scripts and Idenix Pharmaceuticals

NEW YORK, June 5, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Johnson & Johnson (NYSE: JNJ), Pfizer Inc. (NYSE: PFE), Teva Pharmaceutical Industries Limited (NYSE: TEVA), Express Scripts Inc. (NASDAQ: ESRX) and Idenix Pharmaceuticals Inc. (NASDAQ: IDIX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3405-100free.

--
Johnson & Johnson Analyst Notes
On June 2, 2014, Janssen Biotech, a Johnson & Johnson business, announced that Abiraterone acetate (ZYTIGA®) plus prednisone demonstrated statistically significant reductions in PSA levels at six months, the primary endpoint of the IMAAGEN trial. Additionally, the results of the study also found significant reductions in testosterone levels, a key secondary endpoint. According to the Company, the IMAAGEN study evaluates the investigational use of abiraterone acetate plus prednisone (5 mg once daily) in patients with non-metastatic castration-resistant prostate cancer (M0-CRPC) at high risk of developing metastatic disease. Commenting on the results, Charles Ryan, M.D., Professor of Clinical Medicine, Urology at the University of California, San Francisco, and the steering committee chair for IMAAGEN, stated, "This study adds important new insights to the scientific understanding of abiraterone acetate in this patient population on the cusp of disease progression." The full analyst notes on Johnson & Johnson are available to download free of charge at:

http://www.analystsreview.com/Jun-05-2014/JNJ/report.pdf

--
Pfizer Inc. Analyst Notes
On May 29, 2014, Pfizer Inc. (Pfizer) announced that Morris J. Birnbaum, M.D., Ph.D., has joined Pfizer as its Chief Scientific Officer for Cardiovascular and Metabolic Disease Research. Dr. Birnbaum will be based in a key Pfizer R&D hub in Cambridge and will report directly to Rod MacKenzie, Ph.D., Group Senior Vice President and Head of PharmaTherapeutics Research & Development. Commenting on Dr. Birnbaum's appointment, Dr. MacKenzie stated, "He is among the leading contributors to our contemporary understanding of the regulation of intracellular metabolism, and an excellent addition to our team. His scientific credentials and knowledge will help Pfizer pursue our goals to achieve industry leadership from the strong position that we currently hold, and to deliver unique therapies for patients." The full analyst notes on Pfizer are available to download free of charge at:

http://www.analystsreview.com/Jun-05-2014/PFE/report.pdf

--
Teva Pharmaceutical Industries Limited Analyst Notes
On June 2, 2014, Teva Pharmaceutical Industries Limited (Teva) announced a new organizational structure and related executive positions, effective July 1, 2014. Additionally, the Company stated that by July 1, 2014, it will spearhead by two commercial business units - Global Specialty Medicines (GSM) and Global Generic Medicines Group (GGM). The Company stated that Sigurdur Olafsson has been appointed President and CEO of GGM. Teva further announced the appointment of Iris Beck-Codner as Group Executive Vice President, Corporate Marketing Excellence & Communications, and Eric Drapé as Group Executive Vice President, Global Head of Quality. The Company added that Eyal Desheh, Executive Vice President and CFO, will also be responsible for executing corporate efficiency program and will assume joint responsibility for Investor Relations, together with Teva's President and CEO, Erez Vigodman. The full analyst notes on Teva are available to download free of charge at:

http://www.analystsreview.com/Jun-05-2014/TEVA/report.pdf

--
Express Scripts Inc. Analyst Notes
On June 2, 2014, Express Scripts Inc.'s (Express Scripts) stock went down by 2.00%, closing at $70.04. However, for the past one month trading period, Company stock increased by 4.17% compared to the Nasdaq Composite which went up by 2.75% during the same trading period. The full analyst notes on Express Scripts are available to download free of charge at:

http://www.analystsreview.com/Jun-05-2014/ESRX/report.pdf

--
Idenix Pharmaceuticals Inc. Analyst Notes
On June 2, 2014, Idenix Pharmaceuticals Inc.'s (Idenix Pharmaceuticals) stock reflected an increase of 10.05%, closing at $6.90. Over the previous six month trading session, Company stock reflected an increase of 28.48% compared to the Nasdaq Composite which went up by 4.37% during the same trading session. The full analyst notes on Idenix Pharmaceuticals are available to download free of charge at:

http://www.analystsreview.com/Jun-05-2014/IDIX/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review